Study aim: evaluation of the effects of Bromelain, Curcumin and Epigallocatechin in the treatment of outpatient Covid-19 infection. Design: 300 Covid-19 positive patients over 18 year old referred to infectious disease clinic enter the case or control group. After adjusting for age, sex, underlying disease and chest CT scan, patients are divided randomly to receive the main or placebo agent in a double blind manner. Settings and conduct: After obtaining informed consent and Explanation for patients referred to the Urmia Tadbir clinic divide into case or control groups. The intervention group will be prescribed 2 tablets (Bromelain, Curcumin and Epigallocatechin) daily for 5 days, 12 hours along with standard treatment as add on therapy. The placebo group will receive 2 placebo tablets daily for 5 days, 12 hours along with standard treatment as add on therapy. All patients will be followed every day or until the occurrence of hospitalization or death by phone call. Finally the duration and severity of symptoms and the frequency of adverse events will be compared between two groups. Participants/Inclusion and exclusion criteria: Inclusion criteria: Patients with Covid-19 over 18 years Exclusion criteria: history of allergies to green tea, pineapple, latex, turmeric, gastric ulcer in the last 6 months, active bleeding, pregnancy, hepatic or renal failure, coagulation disease, autoimmune disease, gallstones, need of hospitalization Intervention groups: The intervention group will receive 2 capsules, each capsule containing Bromelain, Curcumin, Epigallocatechin daily for 5 days, 12 hours along with standard treatment. Control group will receive 2 placebo tablets for 5 days, 12 hours along with standard treatment. Main outcome variables: Blood oxygen saturation, sense of smell, sense of taste, fever, lung involvement, cough, muscle pain, weakness, gastrointestinal symptoms, death, hospitalization